Physician profile
Muhammad S Ashraf
NPI 1891765038
$1,528.25
in general payments reported to CMS, 2019-2025
26 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $138 · 2021: $226 · 2022: $329 · 2023: $158 · 2024: $58.56 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $371.77 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $217.17 | 2019-2023 | |
| Boston Scientific Corporation | $117.68 | 2024-2025 | Cds - Mct/Cem Monitoring, Watchman Access System |
| Angiodynamics, INC. | $109.91 | 2021-2025 | Auryon Laser System 100-120 Vac |
| E.R. Squibb & Sons, L.L.C. | $91.39 | 2020-2025 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $73.59 | 2019-2023 | Opsumit, Uptravi |
| Medtronic, INC. | $69.33 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $54.33 | 2019 | |
| Pfizer INC. | $53.55 | 2019-2025 | |
| Amgen INC. | $48.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.11 | 2019-2023 | Jardiance |
| Vifor Pharma, INC. | $36.95 | 2019 | |
| Terumo Medical Corporation | $31.63 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.04 | 2023-2024 | Lifevest |
| Ge Healthcare | $21.38 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $20.73 | 2023 | Guideliner |
| Inari Medical, INC. | $19.67 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic Vascular, INC. | $18.27 | 2019 | |
| Cvrx, INC. | $16.25 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $15.96 | 2019 | |
| Daiichi Sankyo INC. | $14.90 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.77 | 2022 | |
| Astellas Pharma US INC | $13.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.